Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;34(123):157-164.
doi: 10.22038/IJORL.2022.58523.3021.

Prognostication of Sino-Nasal Mucormycosis

Prem Sagar  1 , Namrita Mehmi  1 , Anupam Kanodia  1 , Avinash Shekhar Jaiswal  1 , Rajeev Kumar  1 , Chirom Amit Singh  1 , Rakesh Kumar  1 , Alok Thakar  1
Affiliations

Prognostication of Sino-Nasal Mucormycosis

Prem Sagar et al. Iran J Otorhinolaryngol. 2022 Jul.

Abstract

Introduction: For the purpose of prognostication of sinonasal mucormycosis, a detailed analysis of the clinical, diagnostic, therapeutic and outcome parameters has been contemplated.

Materials and methods: Retrospectively data was collected for all patients of sinonasal mucormycosis managed in a tertiary care hospital in last 5years.

Results: Diabetes was the commonest comorbidity among total of 52 cases. Disease extent-wise, 16, 23 and 13 patients had sino-nasal (SN), rhino-orbital (RO) and rhino-orbito-cerebral (ROC) mucormycosis respectively. Median cumulative Amphotericin-B administered was 3.5gms and 94.2% of cases underwent surgical debridement depending on the disease extent. With a median follow-up of 18months, 67% of the patients are alive and disease free, 2% are under treatment and 29% of patients have expired. The mortality rate was 12.5% in SN, 30.5% in RO and 38.5% in ROC mucormycosis. Palatal and orbital involvement is associated with statistically significant mortality risk at one month.

Conclusions: Mortality rate in sino-nasal mucormycosis can be significantly curtailed with prompt control of underlying comorbidity, aggressive medical and adequate surgical management.

Keywords: Amphotericin; Diabetes; Mucormycosis; Orbital mucormycosis; Sino nasal Mucormycosis.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Month-wise presentation of patients based on the date of hospitalization
Fig 2
Fig 2
Patient distribution based on the initiation of the treatment post-hospitalization
See this image and copyright information in PMC

References

    1. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases. Clin Infect Dis. 2005;41(5):634–653. - PubMed
    1. Vaughan C, Bartolo A, Vallabh N, Leong SC. A meta-analysis of survival factors in rhino-orbital-cerebral mucormycosis-has anything changed in the past 20 years? Clin Otolaryngol. 2018;43(6):1454–1464. - PubMed
    1. Raizada N, Jyotsna VP, Kandasamy D, Xess I, Thakar A, Tandon N. Invasive fungal rhinosinusitis in patients with diabetes. J Infect Dev Ctries. 2018;12:09 SE–Original Articles). - PubMed
    1. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Heal. 2018;6(12):e1352–e1362. - PMC - PubMed
    1. Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014: 85–90. - PubMed

LinkOut - more resources